Imaging and clinical outcome of non-small cell lung cancer

Gerald Steve Michael Alexander Kerner

    Onderzoeksoutput

    1886 Downloads (Pure)

    Samenvatting

    Gerald Kerner, born in Curaçao, showed in his thesis that a specific group of patients with non-small cell lung cancer (NSCLC) treated with the ALK inhibitor crizotinib, in 46% of the cases PET/CT was able to show progressive disease earlier time point compared with CT.
    He also showed with a specifiec PET tracer that in NSCLC tumors are dynamically hypoxic. This is related to resistance to therapy. Furthermore, he evaluated a new technique for response assessment with PET/CT in lung cancer. However, he showed that this new technique is not reliable for this type of response assessment.
    He also showed that the combination of the chemotherapeutic agent gemcitabine combined with radiotherapy is safe and effective in treating locally advanced NSCLC.
    Lastly, he described the frequency of genetic mutations within a NSCLC population in the Northern Netherlands. The presence of these genetic mutations EGFR and KRAS are associated with certain therapeutic choices.
    Originele taal-2English
    KwalificatieDoctor of Philosophy
    Toekennende instantie
    • Rijksuniversiteit Groningen
    Begeleider(s)/adviseur
    • Groen, Harry, Supervisor
    • Pruim, Jan, Supervisor
    Datum van toekenning11-mei-2016
    Plaats van publicatie[Groningen]
    Uitgever
    Gedrukte ISBN's978-90-367-8834-2
    Elektronische ISBN's978-90-367-8833-5
    StatusPublished - 2016

    Citeer dit